For the Inventor, By the Inventor

Enter assignee name

Cambridge, MA, United States of America

Mersana Therapeutics, Inc.

USPTO Granted Patents = 36

% Expired Patents = 16.7

EPO Patents = 13

Trademarks = 3

Forward Citations = 279

Loading Chart...

Loading Chart...

44 inventors (with patents filed for the assignee):

Timothy B Lowinger (29 out of 48 patents)

Aleksandr V Yurkovetskiy (28 out of 31 patents)

Mao Yin (22 out of 25 patents)

4. Joshua D Thomas (19 out of 21 patents)

5. Cheri A Stevenson (18 out of 31 patents)

6. Natalya D Bodyak (17 out of 17 patents)

7. Patrick R Conlon (14 out of 28 patents)

8. Charles E Hammond (13 out of 13 patents)

9. Dmitry R Gumerov (11 out of 11 patents)

10. Eugene W Kelleher (7 out of 12 patents)

11. Dorin Toader (6 out of 6 patents)

12. Peter U Park (5 out of 33 patents)

13. Jeremy R Duvall (4 out of 4 patents)

14. Keith W Bentley (4 out of 4 patents)

15. Bingfan Du (4 out of 8 patents)

Core Competencies:

Antibody Drug Conjugates

Sting Agonists

Peptide Linkers

NaPi2b-targeted

Pyrrolobenzodiazepines

Monoclonal Antibodies

Protein-Polymer Conjugates

Auristatin Compounds

Pharmaceutical Formulations

Biocompatible Conjugates

Modified Polymers

Biodegradable Conjugates

36 patents: Sort by Forward Citations

1. 12440576 - Antibody drug conjugates comprising sting agonists (2025-10-14),

2. 12156870 - Antibody drug conjugates comprising sting agonists (2024-12-03),

3. 11964025 - Peptide-containing linkers for antibody-drug conjugates (2024-04-23),

4. 11964024 - B7H4-targeted antibody-drug conjugates and methods of use thereof (2024-04-23),

5. 11939343 - Sting agonist compounds and methods of use (2024-03-26),

6. 11786605 - Site specific antibody-drug conjugates with peptide-containing linkers (2023-10-17),

7. 11638760 - Pyrrolobenzodiazepine antibody conjugates (2023-05-02),

8. 11596694 - Compositions and methods for predicting response to NaPi2b-targeted therapy (2023-03-07),

9. 11518812 - Monoclonal antibodies against HER2 epitope and methods of use thereof (2022-12-06),

10. 11407825 - NaPi2b-targeted polymer antibody-drug conjugates and methods of use thereof (2022-08-09),

11. 11155567 - Sting agonist compounds and methods of use (2021-10-26),

12. 11135307 - Peptide-containing linkers for antibody-drug conjugates (2021-10-05),

13. 10947317 - NaPi2b-targeted antibody-drug conjugates and methods of use thereof (2021-03-16),

14. 10660901 - Pyrrolobenzodiazepines and conjugates thereof (2020-05-26),

15. 10603386 - Protein-polymer-drug conjugates (2020-03-31),

Company Overview

Mersana Therapeutics, Inc. is a biotechnology company based in Cambridge, MA, specializing in the development of innovative antibody-drug conjugates (ADCs) for the treatment of cancer. The company focuses on leveraging its proprietary platform to create therapies that enhance the efficacy and safety of cancer treatments. Mersana is dedicated to advancing its pipeline of ADC candidates, aiming to address unmet medical needs in oncology through targeted therapies that improve patient outcomes.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

36 Patents

#78 in Cambridge, MA

#561 in Massachusetts

#9,516 in US

#18,745 in the World

Cambridge, MA, United States of America

Mersana Therapeutics, Inc.

Forward Citations = 279

44 inventors:

Timothy B Lowinger (29 out of 48 patents)

Aleksandr V Yurkovetskiy (28 out of 31 patents)

Mao Yin (22 out of 25 patents)

4. Joshua D Thomas (19 out of 21 patents)

5. Cheri A Stevenson (18 out of 31 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Mersana Therapeutics, Inc.. Retrieved from https://idiyas.com/company/mersana-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…